

SEARCH
Sunday, February 05, 2023
STATIN SIDE EFFECTS
Statin side effects from 2 patients: depression, amnesia, incredible fatigue, chest pain, insomnia
“That was the worst I ever felt in my life,” notes Katherine Faraday, MD in the wonderful documentary Statin Nation.
“There were times when I wondered if I really wanted to go on living.”
Below is the quote of exactly what she says in the movie about the side effects she experienced—fatigue, depression, memory loss, colitis, and dry eyes—and how neither she nor her doctor realized for 2 years that ALL of the problems she had developed were being caused by the Lipitor (atorvastatin) she was taking to lower her cholesterol.
Read the entire article | Email this article
Monday, August 12, 2019
STATINS
Taking a statin for more than 2 years increases the risk of diabetes 3.3-fold
Taking a statin for more than 2 years increases the risk of diabetes 3.3-fold according to a 2019 study.
Read the entire article | Email this article
Monday, July 29, 2019
STATINS
How much longer will you live if you take a statin for 5 years? 13 days.
How much longer will you live if you take a statin for 5 years?
13 days according to a 2019 analysis by researchers from Denmark.
That’s it, 13 days.
To put this in perspective, the authors of the paper noted that “A different study evaluated the effects of regular exercise and a calorie restricted diet in healthy males, [demonstrated] a postponement of death by 6.2 months [189 days],” and “smoking cessation in a high-risk population postponed death by around 31 months [930 days].”
So if you stop smoking, you will live, on average, an extra 930 days. If you exercise and reduce your calories, you will live, on average, an extra 189 days. And if you take a statin, you will live, on average, an extra 13 days.
Read the entire article | Email this article
Friday, April 05, 2019
STATINS
High-intensity statin therapy increases risk of acute kidney injury by 16%
High-intensity statin therapy was found to increase the risk of hospitalization for acute kidney injury by 16% compared to non-users during a median follow-up of 4.6 years according to a new study.
Read the entire article | Email this articleSTATINS
High-intensity statin therapy increases risk of acute kidney injury in those older than 75 by 22%
High-intensity statin therapy was found to increase the risk of hospitalization for acute kidney injury in those over 75-years by 22% compared to non-users during a median follow-up of 4.6 years according to a new study.
Read the entire article | Email this articleSTATINS
High-intensity statin therapy increases risk of acute kidney injury in those 65-75 by 9%
High-intensity statin therapy was found to increase the risk of hospitalization for acute kidney injury in those 65-75 years by 9% compared to non-users during a median follow-up of 4.6 years according to a new study.
Read the entire article | Email this articleSTATINS
High-intensity statin therapy increases risk of acute kidney injury in women by 29%
High-intensity statin therapy was found to increase the risk of hospitalization for acute kidney injury in women by 29% compared to non-users during a median follow-up of 4.6 years according to a new study.
The study showed that the risk of hospitalization for acute kidney injury with high-intensity statin use was greater among women than men.
The authors of the study speculated that the reason for this “may be due to higher blood levels of statin at a given dose among women than in men, due to the generally lower body size of women.”
Read the entire article | Email this article
Sunday, October 14, 2018
STATINS & CANCER
Statins do NOT increase cancer survival, may increase risk of death 7%
Statins do not increase cancer survival as some studies have claimed.
When researchers eliminated biases from study designs, they found that there was no difference in cancer survival between statin users and non-users.
There was no difference in cancer survival between users and non-users (0% difference), but there was a 7% increased risk of dying overall in statin users versus non-users during the 3-year follow-up period, but this difference was not statistically significant.
Read the entire article | Email this article
Friday, August 17, 2018
BOOK
Book: The Case Against Statins
I just published a book called The Case Against Statins.
It is a collection of articles that I have written about statins over the past 11 years.
It contains evidence that:
- Statins are not effective.
- Statins increase atherosclerosis.
- Statins increase the risk of heart attacks.
- Statins increase the risk of certain cancers.
- Statins increase the risk of diabetes.
- Statins increase the risk of Parkinson’s.
- Statins increase the risk of Alzheimer’s.
- Statins increase the risk of ALS.
- Statins increase the risk of cataracts.
- Statins increase the risk of kidney failure.
- Statins increase the risk of liver dysfunction.
- Statins increase erectile dysfunction.
- Statins increase muscle fatigue.
- Statins can cause muscle rupture.
- Statins have an immunosuppressive effect.
- Statins increase the risk of dying.
This book is just about statins, but the problem is not just with statins.
It is a problem with most drugs given long-term.
Read the entire article | Email this article
Wednesday, August 01, 2018
STATINS & CANCER
Prolonged use of statins associated with a 18% increased risk of lung cancer
Prolonged use of statins for more than 4 years was associated with an 18% increased risk of lung cancer according to a recent analysis of data from 574 UK general practices from 1998-2008.
Read the entire article | Email this articleSTATINS & CANCER
Prolonged use of statins associated with a 23% increased risk of colorectal cancer
Prolonged use of statins for more than 4 years was associated with a 23% increased risk of colorectal cancer according to a recent analysis of data from 574 UK general practices from 1998-2008.
Prolonged use of atorvastatin (Lipitor) for more than 4 years was associated with a 51% increased risk of colorectal cancer.
Read the entire article | Email this articleSTATINS & CANCER
Prolonged use of statins associated with a 29% increased risk of bladder cancer
Prolonged use of statins for more than 4 years was associated with a 29% increased risk of bladder cancer according to a recent analysis of data from 574 UK general practices from 1998-2008.
Read the entire article | Email this article
Sunday, June 10, 2018
STATINS
Statins increase risk of Type 2 diabetes 46% due to decreased insulin secretion and sensitivity
“Statin treatment increased the risk of type 2 diabetes by 46%, attributable to decreases in insulin sensitivity and insulin secretion,” concludes a 2015 study that followed 8,749 non-diabetic participants, 45– to 73-years-old, for 5.9 years.
Read the entire article | Email this article
Monday, May 28, 2018
STATINS & CANCER
People given a statin had 25% more new cancers
People given the statin, pravastatin (Pravachol), had 25% more cancer than those given a placebo in the PROSPER trial.
- 65% more breast cancer
- 46% more gastrointestinal cancer
- 12% more respiratory cancer
- 41% more other cancers
- and they did not including non-melanoma skin cancer.
(Previous studies have found that statins increase the risk of non-melanoma skin cancers.)
Sunday, May 27, 2018
STATINS & CANCER
Women given a statin (pravastatin) had 12-times as much breast cancer
Women given the statin, pravastatin (Pravachol), had 12-times as much breast cancer as women given a placebo in the CARE trial.
Drug companies and their paid researchers have tried to convince people that statins lower the risk of cancer, but this study and many others suggest that the exact opposite is true — that statins increase the risk of cancer, not decrease the risk.
Read the entire article | Email this article
Saturday, May 26, 2018
STATINS & CANCER
Long-term statin use increases breast cancer 2-fold
Long-term statin use (10 years or more) is associated with a more than 2-fold increased risk of breast cancer according to researchers at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
Drug companies and their paid researchers have tried to convince people that statins lower the risk of cancer, but this study and many others suggest that the exact opposite is true — that statins increase the risk of cancer, not decrease the risk.
Read the entire article | Email this article
Thursday, May 17, 2018
STATINS
2.8 times more people given lovastatin died than those given a placebo (0.50% vs 0.18%)
In the first statin study called the Expanded Clinical Evaluation of Lovastatin (EXCEL) study (1991), all-cause mortality was 2.8 times greater in people given lovastatin than those given a placebo (0.50% vs 0.18%) during the first year of follow-up as noted in a 1992 paper published in the British Medical Journal titled Should there be a moratorium on the use of cholesterol lowering drugs?
Read the entire article | Email this articleSTATINS
While statin use increased 68% (1999-2005), heart attacks increased 16%, strokes 45%!
Statin use among US adults increased by 68% from 1999 to 2005, from 8% of people surveyed to 13.4% of people surveyed.
How much do you think this reduced heart attacks, strokes and coronary heart disease?
Would you be surprised to learn that during this time that:
- Heart attacks increased by 16%!
(from 3.4% to 3.7%) - Strokes increased by 45%!
(from 2.0% to 2.9%) - Coronary heart disease increased by 32%!
(from 2.8% to 3.7%) - Type 2 diabetes increased by 32%!
(from 7.8% to 10.3%) - People with one or more of these conditions increased by 19%!
(from 13.4% to 16%)
Do you believe that statins reduce the risk of heart attack, stroke and death?
I do not.
The results of the study mentioned above suggests the exact opposite.
Read the entire article | Email this article
Tuesday, May 08, 2018
PARKINSON’S
Low cholesterol levels associated with 2.3 times greater risk of Parkinson’s disease
The one-third of people with the highest cholesterol levels were 57% less likely to get Parkinson’s during a 20-year follow-up compared to the one-third of people with the lowest cholesterol levels according to a recent study.
The one-third of people with the middle cholesterol levels were 44% less likely to get Parkinson’s compared to the one-third of people with the lowest cholesterol levels.
The say this the other way, the one-third of people with the lowest cholesterol levels were 2.3 times more likely to get Parkinson’s than the one-third of people with the highest cholesterol levels, and they were 1.8 times more likely to get Parkinson’s compared to the one-third of people with the middle cholesterol levels.
“Our study suggests that lowering cholesterol unnecessarily actually may harm the brain,” Xuemei Huang, MD, PhD lead author of the study was quoted as saying.
Read the entire article | Email this articleSTATINS
Statins increase risk of Parkinson’s Disease by 58%
The most popular statins increase the risk of Parkinson’s Disease by 58% according to new study.
These are the lipophilic statins, meaning that they dissolve in fats, which include atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pitavastatin (Livalo), simvastatin (Zocor).
Read the entire article | Email this articleSTATINS
Taking both a statin and a nonstatin to lower cholesterol increases risk of Parkinson’s by 95%
People taking both a statin and a nonstatin to lower cholesterol levels had a 95% increased risk of Parkinson’s compared to people taking neither according to a new study.
Nonstatin cholesterol-lowering drugs included fenofibrate (Trilipix, Tricor, Triglide, Antara, Lipofen, Fibricor, Lofibra, and Fenoglide), ezetimibe (Zetia), and niacin.
This study found that the most popular statins increase the risk of Parkinson’s Disease by 58%.
These are the lipophilic statins, meaning that they dissolve in fats, which include atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pitavastatin (Livalo), simvastatin (Zocor).
Read the entire article | Email this article
Friday, May 04, 2018
STATINS & ALZHEIMER’S
Statin use is associated with a 1% to 12% increased risk of Alzheimer’s
Statin use is associated with a 1% to 12% increased risk of Alzheimer’s according to an analysis of data on 30,343,035 persons aged 40 to 65 years between January 1, 2008, and December 31, 2012 as noted in an article on Medscape (Melville, 2016).
Reference
Melville NA. Statin Use Linked to Increased Parkinson’s Risk. American Neurological Association (ANA) 2016 Annual Meeting, Presented October 16, 2016; Abstract S137: http://www.medscape.com/viewarticle/870996.
The article on Medscape notes:
“We identified 20,000 Parkinson’s disease patients and looked at whether using statins was associated with a higher or lower risk, and we found people using statins have a higher risk of the disease, so this is the opposite of what has been hypothesized,” senior author Xuemei Huang, MD, PhD, vice chair for research at Penn State College of Medicine, Hershey, Pennsylvania, told Medscape Medical News.
The same is true for Alzheimer’s — it’s the opposite of what has been hypothesized.
(The same research group found that statin use was found to be associated with a 58% increased risk of Parkinson’s.)
Read the entire article | Email this article
Monday, April 09, 2018
STATINS & ALS
Rosuvastatin (Crestor) increases risk of Amyotrophic Lateral Sclerosis (ALS) 9-fold
Rosuvastatin (Crestor), a statin to lower cholesterol levels, is associated with a 9-fold increase in Amyotrophic Lateral Sclerosis (ALS) as noted in an article by Dr. Malcolm Kendrick, author of The Great Cholesterol Con and the book Doctoring Data.
Read the entire article | Email this articleSTATINS & ALS
Pravastatin (Pravachol) increases risk of Amyotrophic Lateral Sclerosis (ALS) 16-fold
Pravastatin (Pravachol), a statin to lower cholesterol levels, is associated with a 16-fold increase in Amyotrophic Lateral Sclerosis (ALS) as noted in an article by Dr. Malcolm Kendrick, author of The Great Cholesterol Con and the book Doctoring Data.
Read the entire article | Email this articleSTATINS & ALS
Atorvastatin (Lipitor) increases risk of Amyotrophic Lateral Sclerosis (ALS) 17-fold
Atorvastatin (Lipitor), a statin to lower cholesterol levels, is associated with a 17-fold increase in Amyotrophic Lateral Sclerosis (ALS) as noted in an article by Dr. Malcolm Kendrick, author of The Great Cholesterol Con and the book Doctoring Data.
Read the entire article | Email this articleSTATINS & ALS
Simvastatin (Zocor and FloL) increases risk of Amyotrophic Lateral Sclerosis (ALS) 23-fold
Simvastatin (Zocor and FloL), a statin to lower cholesterol levels, is associated with a 23-fold increase in Amyotrophic Lateral Sclerosis (ALS) as noted in an article by Dr. Malcolm Kendrick, author of The Great Cholesterol Con and the book Doctoring Data.
Read the entire article | Email this articleSTATINS & ALS
Lovastatin (Altoprev) increases risk of Amyotrophic Lateral Sclerosis (ALS) 107-fold
Lovastatin (Altoprev), a statin to lower cholesterol levels, is associated with a 107-fold increase in Amyotrophic Lateral Sclerosis (ALS) as noted in an article by Dr. Malcolm Kendrick, author of The Great Cholesterol Con and the book Doctoring Data.
Read the entire article | Email this article
Tuesday, March 27, 2018
STATINS & CANCER
Do statins increase cancer? Yes, according to three doctors
Do statins increase cancer?
Yes, according to a letter published in Current Oncology.
The letter starts out by saying “prospective data suggest that statins actually increase cancer in certain segments of the population.”
Here are other quotes from the letter.
Read the entire article | Email this article
Monday, July 17, 2017
STATINS
Type 1 diabetics taking statins 1-6 years 3-times more likely to have cognitive impairment
Type 1 diabetics taking statins for 1-6 years were 3.2 times more likely to have cognitive impairment compared to Type 1 diabetics who had never taking statins.
“Statin use was associated with cognitive impairment, particularly affecting memory, in these middle-aged adults with childhood-onset [type 1 diabetes], whom at this age, should not yet manifest age-related memory deficits,” the authors of the paper concluded.
They also note:
“Animal and cell culture studies show that statins can damage cerebral gray and white matter, thereby affecting cognitive function. Findings from human studies remain controversial; early observational studies reported that statin use negatively affected cognition, especially memory, while more recent studies have not replicated these findings.”
Read the entire article | Email this articleSTATINS
Type 1 diabetics taking statins 7-12 years 5-times more likely to have cognitive impairment
Type 1 diabetics taking statins for 7-12 years were 4.8 times more likely to have cognitive impairment compared to Type 1 diabetics who had never taking statins.
“Statin use was associated with cognitive impairment, particularly affecting memory, in these middle-aged adults with childhood-onset [type 1 diabetes], whom at this age, should not yet manifest age-related memory deficits,” the authors of the paper concluded.
They also note:
“Animal and cell culture studies show that statins can damage cerebral gray and white matter, thereby affecting cognitive function. Findings from human studies remain controversial; early observational studies reported that statin use negatively affected cognition, especially memory, while more recent studies have not replicated these findings.”
Read the entire article | Email this article
Tuesday, June 27, 2017
STATINS
Pravastatin increases new cancers by 25% in the elderly
There were 25% more new cancers in elderly people 70-82 who were given 40 mg of pravastatin (Pravachol) per day to lower cholesterol compared to those given a placebo according to the PROSPER trial.
Read the entire article | Email this article
Friday, May 26, 2017
STATINS
People 75 and older taking pravastatin (Pravachol) were 34% more likely to die over 8 years
People 75-years and older without cardiovascular disease who took the statin, pravastatin (Pravachol, 40 mg/day), to lower cholesterol were 34% more likely to have died during the 8 year study than people of the same age not taking a statin although the difference did not quite reach statistical significance.
(There was a 7% chance that the difference between the two groups was due to random chance, but this is close enough for me.)
There were 92 deaths in the pravastatin group versus 65 deaths in the non-statin group.
At the very least this means that pravastatin (Pravachol) provides no benefit to people of this age, and at worst, it means that pravastatin (Pravachol) increases the risk of death considerably.
Read the entire article | Email this articleSTATINS
People 65-74 taking pravastatin (Pravachol) were 8% more likely to die over 8 years
People 65- to 74-years-old without heart disease who took the statin, pravastatin (Pravachol, 40 mg/day), to lower cholesterol were 8% more likely to have died during the 8 year study than people of the same age not taking a statin although the difference was not statistically significant.
There were 141 deaths in the pravastatin group versus 130 deaths in the non-statin group.
At the very least this means that pravastatin (Pravachol) provides no benefit to people of this age, and at worst, it means that pravastatin (Pravachol) increases the risk of death.
Read the entire article | Email this article
Monday, March 27, 2017
STATINS
Increasing statin usage not associated with decreasing coronary heart disease mortality
“Among the [twelve (12)] Western European countries studied, the large increase in statin utilisation between 2000 and 2012 was not associated with [coronary heart disease] mortality, nor with its rate of change over the years,” notes a recent study.
Read the entire article | Email this article
Sunday, March 26, 2017
STATINS
Statin use is associated with a 10-13% increased risk of cataracts
Statin use is associated with a 10-13% increased risk of cataracts according to a new paper.
Read the entire article | Email this article
Thursday, January 05, 2017
STATINS & PARKINSONS
Statin use is associated with a 61% greater risk of Parkinson’s disease
Statin use is associated with a 61% greater risk of Parkinson’s disease according to an analysis of data on 30,343,035 people aged 40 to 65 years between January 1, 2008 and December 31, 2012.
This was after adjusting for age, sex, and other comorbidities, such as hyperlipidemia, diabetes, hypertension, and coronary artery disease.
“We identified 20,000 Parkinson’s disease patients and looked at whether using statins was associated with a higher or lower risk, and we found people using statins have a higher risk of the disease, so this is the opposite of what has been hypothesized,” senior author Xuemei Huang, MD, PhD, vice chair for research at Penn State College of Medicine, Hershey, Pennsylvania, told Medscape Medical News.
“Our study suggests that lowering cholesterol unnecessarily actually may harm the brain,” Xuemei Huang, MD, PhD lead author of the study was quoted as saying.
Previous research has failed to recognize this or reported the opposite, that statins lower the risk of Parkinson’s, because previous studies have failed to adjust for cholesterol levels.
Read the entire article | Email this articleSTATINS & PARKINSONS
Statin use is associated with a 1-12% greater risk of Alzheimer’s disease
Statin use is associated with a 1-12% greater risk of Alzheimer’s disease according to an analysis of data on 30,343,035 people aged 40 to 65 years between January 1, 2008, and December 31, 2012.
Read the entire article | Email this article
Wednesday, September 21, 2016
STATINS
While statin use increased 68% (1999-2005), heart attacks increased 16%, strokes 45%!
How much do you think this reduced heart attacks, strokes and coronary heart disease?
Would you be surprised to learn that during this time that:
Heart attacks increased from 3.4% to 3.7%, a relative increase of 16%!
Strokes increased from 2.0% to 2.9%, a relative increase of 45%!
Coronary heart disease increased from 2.8% to 3.7%, a relative increase of 32%!
Type 2 diabetes increased from 7.8% to 10.3%, a relative increase of 32%!
People with one or more of these conditions increased from 13.4% to 16%, a relative increase of 19%!
Do you believe that statins reduce the risk of heart attack, stroke and death?
I do not.
The results of the study mentioned above suggests the exact opposite.
Below is more evidence that statins are not the wonderful, life-saving drugs that we have been led to believe, but instead the exact opposite: that statins are causing harm.
Read the entire article | Email this article
Friday, September 16, 2016
CONFLICTS OF INTEREST
‘Conflict of interest ... is a cancer eating at the core of medical research,’ says Dr Kailash Chand
“Medical research is fraught with incompetence, careerism and fraud. Conflict of interest ... is a cancer eating at the core of medical research,” Dr. Kailash Chand, deputy chairman of the British Medical Association, “who is an outspoken critic of what he regards as industry-driven hype surrounding statins” was quoted as saying in a Dec 2015 article published on the Daily Mail Online.
“The more embedded the financial and other interests in the outcome of a study, the more likely the findings are going to be false.”
“We need doctors to concentrate on research that matters to patients, not their careers or the advance of drug companies.”
Read the entire article | Email this articleCONFLICTS OF INTEREST
Statin benefits have been ‘grossly exaggerated’ says Dr. Kailash Chand of the British Medical Assoc.
Dr. Kailash Chand, deputy chairman of the British Medical Association, believes that statin benefits have been “grossly exaggerated” and that there is a lack of transparency over the statins’ side effects,’ as he was quoted as saying in a Dec 2015 article published on the Daily Mail Online as saying.
Read the entire article | Email this articlePage 1 of 3. Go to page 1 2 3 >
QUICKLINKS AND VIEW OPITONS
QUOTE OF THE DAY
Books by Larry Hobbs available on Amazon


© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.